SVRA — Savara Inc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1160308 ·
Last close
$5.56
Market Cap
$1.14B
52W High
$6.47
52W Low
$4.73
ADV30
1,678,361
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -38,137,000 | -37,284,000 | 221,645,000 | 38,791,000 | 45,606,000 |
| Dec 2025 | 0 | — | -33,419,000 | -32,236,000 | 253,436,000 | 33,180,000 | 50,303,000 |
| Sep 2025 | 0 | — | -30,255,000 | -29,561,000 | 140,924,000 | 16,277,000 | 46,538,000 |
| Jun 2025 | 0 | — | -31,440,000 | -30,401,000 | 163,765,000 | 17,436,000 | 43,281,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-106,894,000
Investing CF
$-8,991,000
Financing CF
$135,293,000
CapEx
$-73,000
Dividends Paid
—
Buybacks
$-5,165,000
EPS Diluted TTM
$-0.55
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-645,371,000
Inventory
—
Receivables
$1,053,000
ST Investments
$163,981,000
EBIT TTM
$-133,251,000
Pretax Income TTM
$-129,482,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -122,763,000 | -118,837,000 | 253,436,000 | 50,303,000 | — | -101,037,000 |
| Dec 2024 | 0 | -102,399,000 | -95,881,000 | 212,879,000 | 41,430,000 | — | -89,088,000 |
| Dec 2023 | 0 | -59,210,000 | -54,698,000 | 177,564,000 | 37,192,000 | — | -51,061,000 |
| Dec 2022 | 0 | -38,043,000 | -38,150,000 | 139,777,000 | 31,999,000 | — | -34,554,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.31
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $9.00 · spot: $5.56 · call volume: 34 · put volume: 582
Expected Move to 2027-02-19:
±$3.62
(65.11%) —
implied range
$1.94 –
$9.18
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| JANX | Janux Therapeutics, Inc. | $1.14B | $18.60 | — |
| OBX | Obsidian Therapeutics, Inc. | $1.16B | $18.70 | — |
| IVA | Inventiva S.A. | $1.11B | $4.70 | — |
| OPK | OPKO HEALTH, INC. | $1.10B | $1.48 | — |
| KURA | Kura Oncology, Inc. | $1.10B | $12.40 | — |
News headlines (Yahoo Finance, 1h cache)
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European
2026-08-24 20:05 · Yahoo
Savara Announces New Employment Inducement Grant
2026-08-20 20:05 · Yahoo
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-11 20:05 · Yahoo
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
2026-07-30 12:05 · Yahoo
Here's Why You Should Add Savara Stock to Your Portfolio Now
2026-07-22 13:21 · Yahoo
What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline
2026-06-27 15:34 · Yahoo
Assessing Savara (SVRA) Valuation As Shares Cool After Strong Long Term Returns
2026-06-08 17:13 · Yahoo
Savara Inc. (SVRA) Reports Q1 Financial Results
2026-05-22 18:43 · Yahoo
What Insmed Stock's Premium Is Actually Buying
2026-08-07 15:39 · Yahoo
Savara Announces Chief Financial and Administrative Officer Transition
2026-06-08 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.